Skip to main content

paxalisib

paxalisib: 6 clinical trials tracked.

paxalisib evidence translation

What we can confirm

6 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about paxalisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (6)

5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform

NCT07391215·Phase 1/Phase 2·UTHR
Recruiting

Primary endpoint: Phase 1b - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in patients with malignant brain tumours

Interventionalopen64 targetStarted 2026-01Completion 2029-061 site · United KingdomInstitute of Cancer Research, United Kingdom

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

NCT06208657·Phase 1/Phase 2
Recruiting

Primary endpoint: Number of participants treated with molecularly-targeted agents in each treatment arm.

Interventionalopen90 targetStarted 2024-07Completion 2035-1214 sites · Australia, CanadaAustralian & New Zealand Children's Haematology/Oncology Group

A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma

NCT05183204·Phase 2
Suspended

Primary endpoint: Progression-free survival, defined as the survival rate at 6 months

Interventionalopen33 targetStarted 2022-02Completion 2026-061 site · United StatesWeill Medical College of Cornell University

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

NCT05009992·Phase 2
Recruiting

Primary endpoint: Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B Only

InterventionalRandomizedopen360 targetStarted 2021-10Completion 2029-0632 sites · Australia, Israel, Netherlands, New Zealand…University of California, San Francisco

A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT04906096·Phase 2
Recruiting

Primary endpoint: Number of participants with Objective Response Rate (ORR)

Interventionalopen25 targetStarted 2021-06Completion 2027-122 sites · United StatesLakshmi Nayak, MD

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

NCT03970447·Phase 2/Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen2,250 targetStarted 2019-07Completion 2030-0650 sites · Australia, Canada, United StatesGlobal Coalition for Adaptive Research